Patents by Inventor Sharif Asad

Sharif Asad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VANIN-1 INHIBITORS
    Publication number: 20250066353
    Abstract: Disclosed herein are bicyclic compounds, including pharmaceutical compositions that include one or more of such compounds. Also disclosed are methods of making functionalized bicyclic compounds. Also disclosed herein are methods of treating diseases and/or conditions (e.g., inflammation and/or cancer) with the bicyclic compounds disclosed herein.
    Type: Application
    Filed: September 20, 2024
    Publication date: February 27, 2025
    Inventors: Dimitrios ILIOPOULOS, David G. HO, Sharif ASAD, Iordanis KARAGIANNIDIS
  • Trk inhibition
    Patent number: 10800760
    Abstract: The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 13, 2020
    Assignee: NANTBIO, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Trk inhibition
    Patent number: 10738033
    Abstract: The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. The present invention also provides compounds of the formula: as defined herein.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 11, 2020
    Assignee: NANTBIO, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • TRK INHIBITION
    Publication number: 20180346450
    Abstract: The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • TRK INHIBITION
    Publication number: 20180346451
    Abstract: The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci